What is the future for UK-based biotechnology? This article reviews the financing of, and governmental support for, the sector and considers the potential impact of new technology in the development of the life sciences.
What is the outlook for medical affairs up to 2030, and what are the advantages for pharma and biotechs from outsourcing this function to external specialists?
The Biotechnology Innovation Organisation (BIO), Developing Countries Vaccine Manufacturers’ Network (DCVMN) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) met at the ‘Global Equity & Timely Access: COVID-19 and Beyond’ meeting in India in October and announced their support for the Berlin Declaration ‘biopharmaceutical industry vision for equitable access in pandemics’.
PharmaMedic's VirtualPharma™ Solution is backed by decades of medical affairs experience and built on four key pillars. Read more to learn how we help pharma and biotech companies of all sizes with flexible solutions.
Navigating the information overload of COVID-19 is a challenge. In this short update, PharmaMedic rounds up some top resources for individuals, pharma and biotech researchers.
